ArticleInternational journal of clinical pediatric dentistry2025
Evaluation of Chitosan (Axiostat®) as a Pulpotomy Agent in Primary Molars: An
Article in International journal of clinical pediatric dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Chitosan pulpotomy medicaments versus conventional agents in primary teeth: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In primary teeth, pulpotomy is a well-established intervention for managing cariously exposed coronal pulp, with formocresol long considered the gold-standard medicament. Recent research focuses on wound-healing phenomena and the use of regenerative materials like chitosan owing to its functional versatility and unique characteristics. Aim: To assess the clinical and radiographic outcomes of using chitosan as a pulpotomy agent in primary molars. Materials and methods: Children aged 4-9 years, free from systemic illnesses and in need of pulpotomy, were selected. About 50 teeth were assigned to two groups: group I (chitosan) and group II (formocresol), and all treated teeth received stainless-steel crowns. Clinical and radiographic parameters were assessed at 1, 3, and 6 months posttreatment. The Chi-squared test was applied to compare the parameters and analyze the differences between the groups at the various time intervals. Results: Group I (chitosan) demonstrated a clinical and radiographic success rate of 95.6%, while group II (formocresol) achieved 100%. The variation between the groups was not statistically significant. Conclusion: The study indicated that chitosan (Axiostat®) can be considered a reliable pulpotomy agent in primary dentition and an effective substitute for formocresol. How to cite this article: Krishna N, Rai K, Manju R,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.